NEW YORK, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology
company focused on the treatment of primary and metastatic liver cancers, announces that after conversations with both Nasdaq and
OTC Markets, the Company is able to effect the change in listing to the OTC Markets more quickly than anticipated. The
Company's common stock will commence trading on the OTCQB on September 15, 2017 under the symbol "DCTH".
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and
metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic
Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure
and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular
Melanoma (OM), and plans to initiate a global registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not
been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been
commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it
has been used at major medical centers to treat a wide range of cancers of the liver.
Forward Looking Statements
Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or
on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can
cause actual results to differ materially from those described. Factors that may cause such differences include, but are not
limited to, uncertainties relating to: the timing and results of the Company’s clinical trials including without
limitation the OM and ICC clinical trial programs, timely enrollment and treatment of patients in the global Phase 3 OM
clinical trial, IRB or ethics committee clearance of the Phase 3 OM and ICC Registration trial protocols from
participating sites and the timing of site activation and subject enrollment in each trial, the impact of the presentations at
major medical conferences and future clinical results consistent with the data presented, approval of Individual Funding Requests
for reimbursement of the CHEMOSAT procedure, the impact, if any of ZE reimbursement on potential CHEMOSAT product use and
sales in Germany, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in
Europe including the key markets of Germany and the UK, the Company’s ability to successfully commercialize the Melphalan
HDS/CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and metastatic
disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, approval of the current or
future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various
indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company’s ability
to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if
any, of the same, uncertainties relating to the timing and results of research and development projects, an orderly transition to
the OTCQB market , and uncertainties regarding the Company’s ability to obtain financial and other resources for any research,
development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our
filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which
speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements
to reflect events or circumstances after the date they are made.
Contact: Scott Gordon President - CoreIR Email: investorrelations@delcath.com
